Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06832865 · ClinicalTrials.gov registry record · Phase 2
ELISA in Relapsed/Refractory MM
A Phase 2 study of Relapsed Refractory Multiple Myeloma and Relapsed Refractory Multiple Myeloma (RRMM), sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT06832865 is a Phase 2 study of Relapsed Refractory Multiple Myeloma and Relapsed Refractory Multiple Myeloma (RRMM) that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 191-participant average among 4 other Relapsed Refractory Multiple Myeloma trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT06832865, a Phase 2 study of Relapsed Refractory Multiple Myeloma and Relapsed Refractory Multiple Myeloma (RRMM), is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior lines of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.
Conditions Studied
Interventions
- DRUG elranatamab
- DRUG Isatuximab SC
- DEVICE Isatuximab SC-OBDS
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-08-14 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06832865
The ClinicalTrials.gov registry entry for NCT06832865 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 191-participant average among 4 other Relapsed Refractory Multiple Myeloma trials with a reported enrollment target (84% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Relapsed Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which elranatamab is the first listed.
NCT06832865 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06832865 about?
NCT06832865 is a clinical study titled "ELISA in Relapsed/Refractory MM". This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior lines of therapy and who have had previous treatment with both immunomodulatory drugs (I...
What is the current status of trial NCT06832865?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-08-14. Estimated completion is 2028-12-01.
What conditions does trial NCT06832865 study?
This clinical trial studies the following conditions: Relapsed Refractory Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM).
What interventions are being tested in trial NCT06832865?
The interventions under investigation include: elranatamab (DRUG), Isatuximab SC (DRUG), Isatuximab SC-OBDS (DEVICE).
Who is sponsoring clinical trial NCT06832865?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06832865 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RECRUITING · Phase 3
-
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Myeloma-Developing Regimens Using Genomics (MyDRUG)
COMPLETED · Phase 1
Explore more on PlainTrial
Relapsed Refractory Multiple Myeloma
All registered trials for this condition
Relapsed Refractory Multiple Myeloma (RRMM)
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.